Patient-derived Xenograft (PDX) Mouse Models 

Recapitulate the tumor and patient heterogeneity and response to treatment using patient-derived xenograft (PDX) mouse models     

Home » Oncology CRO Services » Patient-derived Xenograft (PDX) Mouse Models

Patient-derived xenograft (PDX) mouse models are established from resected tumor samples obtained from oncologic patients that are implanted and grown in immunodeficient mice. However, to fully recapitulate the intricacies between the immune system and the tumor microenvironment, humanized mouse models are recommended instead of immunodeficient mice. Patient-derived xenograft (PDX) mouse models represent the most clinically relevant and predictive tool in your drug development journey, recapitulating the tumor and patient heterogeneity, gene expression, and response to treatment.  

Therefore, experts from InnoSer’s immuno-oncology team recommend the use of PDX mouse models whenever you have carried out initial in vivo studies using cell line-derived (CDX) mouse models and wish to obtain more clinically relevant results. Accordingly, patient-derived xenografts are suitable for evaluating a range of therapies ranging from immunotherapy, antibody, antibody-drug conjugate, and gene therapies to small molecules (cytotoxic drugs). PDX models provide you with a highly predictive in vivo model for therapeutic efficacy evaluation.

Compared to other preclinical in vivo models, patient-derived xenograft models represent more robust models, requiring longer study timelines and the inclusion of different patient samples to capture your compound’s efficacy on patient heterogeneity.  

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Services with patient-derived xenograft (PDX) mouse models from InnoSer:  

  • Well-characterised parental samples (histopathology, hot spot analyses, mutational burden, treatment history, response to treatment). 
  • Complementary in vitro assays using patient-derived organoids (tumoroids).  
  • On-request PDX expansion services.

Interested in the diagnostics, parental genome and growth curves for our validated PDXO platforms

PDXO technical leaflet

Key readouts in patient-derived xenograft (PDX) mouse models: 

Test the efficacy of your treatments with the following readouts: 

  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • Histopathology 

    Example data featuring patient-derived xenograft (PDX) mouse models:

      Related model options

      Oncology Platform Overview

      Highly relevant oncology CRO services to facilitate preclinical drug development.

      Patient-derived organoids (tumoroids)

      Access InnoSer’s high-throughput drug screening capabilities. 

      Immuno-Oncology in vitro Assays

      InnoSer offers oncology CRO services using cancer-associated tumor and microenvironment-associated cell lines (human and rodent).

      AAALAC Accreditation

      InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

      AAALAC logo

      Animal Welfare

      The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

      Need more information?

      If you have any questions about how we can help accelerate your research,

      then let us know